HEALTH

Genentech to Build Plant in California: The South San Francisco-based biotechnology company has chosen Vacaville as the site of a new $150-million manufacturing plant. The company said it looked at 50 sites in several states and Europe before deciding on Vacaville, where it is negotiating to buy a 100-acre site from Chevron Land & Development Co. The new plant, scheduled for completion in late 1997, would initially create 300 jobs. It is expected to be the company’s main manufacturing facility, officials said. Chief Executive G. Kirk Raab said the firm was swayed by local, state and federal incentives in choosing the site. Under a law passed by the Legislature last year, Genentech received a 6% investment tax credit for new biopharmaceutical facilities and a permanent research and development tax credit.